Understanding how autonomic function affects atrial fibrillation recurrence after heart procedure
The Impact of Autonomic Function on Recurrence Following Circumferential Pulmonary Vein Ablation for Atrial Fibrillation
China National Center for Cardiovascular Diseases · NCT06202209
This study is trying to see how the body's nervous system affects the chances of atrial fibrillation coming back after a heart procedure called pulmonary vein isolation.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 100 (estimated) |
| Ages | 18 Years to 75 Years |
| Sex | All |
| Sponsor | China National Center for Cardiovascular Diseases (other gov) |
| Locations | 1 site (Beijing) |
| Trial ID | NCT06202209 on ClinicalTrials.gov |
What this trial studies
This observational study aims to explore the relationship between autonomic nervous system function and the recurrence of atrial fibrillation (AF) following circumferential pulmonary vein isolation (CPVI). By assessing changes in autonomic function in patients diagnosed with paroxysmal AF, the study seeks to identify predictors for both early and late AF recurrence post-ablation. The research is grounded in the hypothesis that improved understanding of autonomic changes can enhance the success rates of AF treatments and potentially lead to better patient outcomes. The study will involve patients who have consented to participate and are willing to undergo CPVI treatment.
Who should consider this trial
Good fit: Ideal candidates for this study are adults aged 18 to 75 diagnosed with paroxysmal atrial fibrillation who are willing to undergo CPVI treatment.
Not a fit: Patients with a history of previous ablation procedures, severe pulmonary diseases, or other significant cardiac conditions may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to improved strategies for preventing atrial fibrillation recurrence, enhancing patient quality of life.
How similar studies have performed: Previous studies have indicated that understanding autonomic function can influence AF treatment outcomes, suggesting potential success for this approach.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Sign the informed consent form; 2. Clearly diagnosed as paroxysmal AF, willing to receive CPVI treatment; 3. A class I or class III antiarrhythmic drug with poor efficacy, or intolerance to drugs. Exclusion Criteria: 1. Diagnosis of sinus rhythm at recruitment; 2. Age is \<18 years old or\> 75 years old; 3. Transthoracic echocardiography suggested a left atrial anterior and posterior diameter of\> 55mm; 4. Previous history of catheter ablation or surgical ablation for AF; 5. Left atrial thrombus recorded by ultrasound or CT; 6. With severe pulmonary diseases; 7. Previous history of cardiac surgery; 8. Patients with hyperthyroidism, atrial septal defect, mitral valve stenosis or severe coronary heart disease who need further treatment; 9. During pregnancy or lactation.
Where this trial is running
Beijing
- Fuwai Hospital, National Center for Cardiovascular Diseases, Chinese Academy of Medical Sciences and Peking Union Medical College — Beijing, China (RECRUITING)
Study contacts
- Study coordinator: yan Yao, PhD
- Email: ianyao@263.net.cn
- Phone: 13901121319
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Atrial Fibrillation Recurrent, Early recurrent atrial arrhythmia, Cardioneuroablation, Automatic function